Drug Profile


Alternative Names: NicErase; NicErase-SL

Latest Information Update: 14 Nov 2003

Price : $50

At a glance

  • Originator Able Laboratories
  • Developer Able Laboratories; Nastech Pharmaceutical Company
  • Class Alkaloids; Drug withdrawal therapies; Piperidines; Smoking cessation therapies
  • Mechanism of Action Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Smoking withdrawal

Most Recent Events

  • 14 Nov 2003 Discontinued for Smoking withdrawal (Intranasal)
  • 29 Dec 1998 Investigation in Smoking withdrawal (Intranasal)
  • 29 Dec 1998 Discontinued-III for Smoking withdrawal in European Union (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top